Citius Pharmaceuticals Inc expected to post a loss of 58 cents a share - Earnings Preview

Citius Pharmaceuticals

10/02/2025 11:06

* Citius Pharmaceuticals Inc  CTXR.OQ   CTXR.O  is expected
to show a rise in quarterly revenue when it reports  results on
February 12 (estimated) for the period ending December 31 2024
    * The Cranford New Jersey-based  company is expected to
report
revenue of $7.061 million, according to the mean estimate from 3
analysts, based on LSEG data.
    * ​LSEG's mean analyst estimate for Citius Pharmaceuticals
Inc is
for a loss of 58 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 3 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts had fallen by
about 50.0%
in the last three months. ​
    * Wall Street's median 12-month price target for Citius
Pharmaceuticals Inc is $8.50​, above​ its last closing price
of $2.67. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Sep. 30 2024  -1.73       -1.50      -1.59     Missed  -6.1
 Jun. 30 2024  -1.24       -1.25      -1.50     Missed  -20
 Mar. 31 2024  -1.50       -1.50      -1.25     Beat    16.7​
 Dec. 31 2023  3.25        3.25       -1.50     Missed  -146.2
 ​​Sep.                    -0.50      -2.00     Missed  -300
 30 2023                                                
 Jun. 30 2023  -1.42       -1.37      -1.50     Missed  -9.1​
 Mar. 31 2023  -0.86       -0.87      -1.75     Missed  -100
 This summary was machine generated February 10 at 11:06 GMT. 
All figures in US dollars unless otherwise stated. (For
questions concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)